Solutions for long-read sequencing in clinical applications

Early detection of mutation populations is possible through the enhanced sensitivity of modern sequencing techniques compared to traditional methods. This is done at the same

sample costs as Sanger sequencing, thereby opening up for improved patient treatment and better use of expensive drugs.

Long-read sequencing is a new technology that offers important advantages for medical diagnostics as compared to the short-read sequencing technologies that are currently dominating the market.

Together with clinicians at Uppsala Academic Hospital (UAH), Pincer Bio AB developed a data analysis product (CLAMP) implementing automated clinical routine for diagnostics of leukemia mutations using long-read sequencing.

Our method has completely replaced Sanger sequencing for screening Chronic Myeloid Leukemia (CML) at UAH. We are now expanding to other applications.

We offer:

    • A complete integrated solution for the data analysis and reporting step
    • Entire chain from sample to report (in collaboration with NGI at SciLifeLab)

Pincer Bio is based on research funded by and in collaboration with Uppsala University, Uppsala Academic Hospital, SciLifeLab, eSSENCE, Swedish e-Science Research Centre (SeRC) and e-Science for Cancer Prevention and Control (eCPC).